<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46767">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01678027</url>
  </required_header>
  <id_info>
    <org_study_id>NCCSTS04-103</org_study_id>
    <nct_id>NCT01678027</nct_id>
  </id_info>
  <brief_title>Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication</brief_title>
  <official_title>Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Center, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Center, Korea</source>
  <oversight_info>
    <authority>National Cancer Center, Korea: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Helicobacter pylori infection is associated with gastric cancer in epidemiological studies.
      However, it is still unknown whether H. pylori eradication is useful and required to prevent
      gastric cancer.

      Gastric cancer risk is increased in family members of gastric cancer patient. Though there
      is no direct evidence that H. pylori infection is a risk factor for gastric cancer in family
      members of gastric cancer, current European guideline recommends H. pylori eradication in
      first-degree relatives of gastric cancer patients.

      In this study, the investigators will evaluate whether H. pylori eradication can reduce
      gastric cancer risk in the first-degree family members of gastric cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Gastric cancer incidence</measure>
    <time_frame>6 years after last participant enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>The incidence of gastric cancer will be compared between the two arms as the participant assigned into either LAC treatment group or placebo group regardless the final H. pylori infection status.
Currently, efficacy of LAC triple therapy shows about 75-85% eradication rate of the H. pylori.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric cancer incidence</measure>
    <time_frame>6 year after last participant enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Incidence of gastric cancer according to the final H. pylori infection status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastric cancer incidence</measure>
    <time_frame>6 year after last participant enrollment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Gastric cancer incidence according to the initial gastric mucosal atrophy grade and intestinal metaplasia grade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1810</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Bacterial Infection Due to Helicobacter Pylori (H. Pylori)</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LAC triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LAC triple therapy</intervention_name>
    <description>Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.</description>
    <arm_group_label>LAC triple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Sibling or offspring of patients with gastric adenocarcinoma confirmed by EGD and
             biopsy

          -  Informed consent should be signed

        Exclusion Criteria:

          -  Gastric cancer history

          -  Other malignancy within the past 5 years

          -  Hereditary cancer family member (HNPCC, FAP)

          -  Peptic ulcer history

          -  Peptic ulcer, esophageal cancer, gastric cancer case found at EGD

          -  H. pylori eradication treatment history

          -  Previous serious side effect to antibiotics

          -  Serious concurrent infection or nonmalignant disease such as liver cirrhosis, renal
             failure, cardiovascular diseases

          -  Pregnant or nursing women

          -  Psychiatric disorder that would preclude compliance, alcoholics

          -  Refuse informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Center, Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
    <phone>+82-31-920-2282</phone>
    <email>cij1224@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center, Korea</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi</state>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Il Ju Choi, M.D., Ph.D.</last_name>
      <phone>+82-31-920-2282</phone>
      <email>cij1224@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Il Ju Choi, M.D.,Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>August 17, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Center, Korea</investigator_affiliation>
    <investigator_full_name>Il Ju Choi</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Family history</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
